Clinical trials: Hepatitis; Epidemic
Hepatitis C
TD-6450 SAD and MAD in Healthy Subjects
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
- Trial name
- NCT02022306
- Testing
- TD-6450
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
HIV Infections
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to…
- Trial name
- NCT00001119
- Testing
- Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine
- Where
- 12 sites in United States, Australia
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis E
Seroprevalence Hepatitis E Infection in Healthy Blood Donors
This is a HEV seroprevalence in the health donors in the Canton Ticino study. The pre-donation sampling pouch of each blood donor coming form the Cantone Ticino region will be collected and tested for HEV serology (IgM and IgG).
- Trial name
- NCT03601221
- Testing
- Sample collection
- Where
- Switzerland
- Volunteers
- 1,447 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Inflammatory Bowel Diseases, Hepatitis B
Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients
Inflammatory bowel disease (IBD) has witnessed a rising incidence globally and in Hong Kong, an area where chronic hepatitis B (CHB) remains endemic.
- Trial name
- NCT04083157
- Testing
- Intradermal hepatitis B vaccine with imiquimod, Intramuscular hepatitis B vaccine with aqueous cream
- Where
- China
- Volunteers
- 104 people
- Sponsor
- The University of Hong Kong
Bacterial Infections, Virus Diseases
Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)
This is a study to assess the safety, tolerability, and immunogenicity of V419 (PR5I) when administered as an infant series at 2, 4, and 6 months of age followed by a toddler dose of DAPTACEL™, Prevnar 13™ and PedvaxHIB™ at 15…
- Trial name
- NCT01337167
- Testing
- V419, DAPTACEL™, PedvaxHIB™
- Volunteers
- 1,473 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to show superiority of simeprevir (SMV) in combination with sofosbuvir for 12 weeks versus a historical control.
- Trial name
- NCT02250807
- Testing
- Simeprevir, Sofosbuvir
- Where
- 6 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Janssen R&D Ireland
HBV
The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
The aim of this study is to compare the BW and metabolic profiles of CHB patient before and after shifting to TAF therapy. In this study, investigators will enroll 100 entecavir and 100 TDF treated CHB patients who will switch to…
- Trial name
- HBV (NCT04886336)
- Where
- Taiwan
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Hepatitis B
Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y
Subjects who had not responded to previous hepatitis B vaccination were vaccinated with either the adjuvanted HBV-MPL vaccine or Engerix™-B vaccine according to a three-dose vaccination schedule (0, 1, 2 months) and boosted at…
- Trial name
- NCT00698061
- Testing
- HBV-MPL vaccine 208129, Engerix™-B
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the…
- Trial name
- NCT04891770
- Testing
- Tenofovir Alafenamide, VIR-2218, Nivolumab
- Where
- 26 sites in Australia, Denmark and 6 more
- Volunteers
- 103 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
The objectives are to demonstrate that entecavir has antiviral activity undetectable HBV DNA measured, the Roche AmplicorTM PCR at Week 48, and to assess the safety and the pharmacokinetic of entecavir in Japanese patients with…
- Trial name
- NCT01037166
- Testing
- Entecavir
- Where
- 16 sites in Japan
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis, Autoimmune
Phase II AutoImmune Hepatitis
This is a Phase IIa open label adaptive design dose finding study in male and female patients with autoimmune hepatitis (AIH) with compensated liver function currently under standard of care.
- Trial name
- NCT03593460
- Testing
- Synthetic PreImplantation Factor
- Sponsor
- Christopher O'Brien, MD
Alcoholic Hepatitis
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Drinking large amount of alcohol can cause damage to the liver. If the liver is severely injured by alcohol it can become very inflamed and this condition is called alcoholic hepatitis.
- Trial name
- CREED (NCT04544020)
- Testing
- NG feeding
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Aberdeen
Alcoholic Hepatitis
Protective Immune Mechanisms in Alcoholic Hepatitis
The purpose of this study is to investigate the production, effects and interactions of the hepato-protective cytokine interleukine (IL)-22 in patients with alcoholic hepatitis.
- Trial name
- AHIL (NCT01918462)
- Where
- Denmark
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Blood Disease, Hepatitis, Viral, Human
Hepatitis Delta Infections in Hemophiliacs
To elucidate the role of hepatitis delta virus (HDV) in the development of chronic liver disease in patients with hemophilia.
- Conditions
- Blood Disease, Hepatitis, Viral, Human, Liver Diseases, Hemophilia A
- Trial name
- NCT00005305
- Testing
- No interventions - observational study
- Volunteers
- 61 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
The primary objective of the study is to determine the number of adverse events (AEs) reported by chronic hepatitis C (CHC) patients receiving at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) at the 2 sentinel sites and…
- Trial name
- NCT03208322
- Testing
- Non-Interventional
- Where
- 2 sites in Mexico
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection.
- Trial name
- NCT00037622
- Testing
- ACH-126, 443 (beta-L-Fd4C)
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis D
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Retrospective and prospective, pharmacological, multicentre, non-profit observational study. Consecutive patients with HDV-related compensated cirrhosis starting Bulevirtide 2 mg/day from September 2019 to December 2025 will be…
- Trial name
- SAVE-D (NCT06397859)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 266 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Hepatitis B
Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis
The purpose of this study is to determine if DNA vaccination of chronic HBV patients under treatment with NRTI can restore T-cell responsiveness and delay virologic reactivation after treatment discontinuation.
- Trial name
- VAC-ADN (NCT00536627)
- Testing
- DNA vaccine pCMVS2.S
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C
Treatment as Prevention for Hepatitis C in Iceland
The main aim of this study is to test in the Icelandic population the hypothesis that a nationwide treatment program which offers effective treatment to all known cases of Hepatitis C with the aim of halting HCV (Hepatitis C…
- Trial name
- TraPHepC (NCT02647879)
- Where
- Iceland
- Volunteers
- 1,000 people
- Sponsor
- Landspitali University Hospital
Chronic Hepatitis C
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic…
- Trial name
- NCT01178996
- Testing
- Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 552 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.